Page last updated: 2024-08-25

7-hydroxystaurosporine and ER-Negative PR-Negative HER2-Negative Breast Cancer

7-hydroxystaurosporine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aprelikova, O; Bennett, CN; Caplen, NJ; Chu, IM; Green, JE; Hollingshead, MG; Luger, D; Michalowski, AM; Mittereder, LR; Piwinica-Worms, H; Shou, J; Tomlinson, CC	1

Other Studies

1 other study(ies) available for 7-hydroxystaurosporine and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Breast cancer research : BCR, 2012, Jul-19, Volume: 14, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cluster Analysis; Deoxycytidine; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Protein Kinase Inhibitors; Protein Kinases; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering; Staurosporine; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2012

Article

Year

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.

Breast cancer research : BCR, 2012, Jul-19, Volume: 14, Issue:4

Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cluster Analysis; Deoxycytidine; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Protein Kinase Inhibitors; Protein Kinases; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering; Staurosporine; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2012